Idacio Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease or Ulcerative Colitis (6 count)
- RxCUI
- 2640870
- RxNorm name
- Idacio Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease or Ulcerative Colitis (6 count)
- Display name
- Idacio Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease or Ulcerative Colitis (6 count)
- Full name
- Idacio Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease or Ulcerative Colitis (6 count)
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:56
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761255 | Idacio | adalimumab-aacf | 351(k) Biosimilar | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Idacio | ADALIMUMAB-AACF | Fresenius Kabi USA, LLC | 43de75ac-1a37-4609-9edd-68bda2448a47 | 2026-01-30 | Boxed warning, Warnings, Adverse reactions | 2640870 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 43de75ac-1a37-4609-9edd-68bda2448a47 | Idacio Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease or Ulcerative Colitis (6 count) | SY | 7 | These highlights do not include all the information needed to use IDACIO safely and effectively. See full prescribing information for IDACIO. IDACIO® (adalimumab-aacf) injection, for subcutaneous use Initial U.S. Approval: 2022 IDACIO® (adalimumab-aacf) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between | 20260130 |
| 43de75ac-1a37-4609-9edd-68bda2448a47 | {6 (0.8 ML adalimumab-aacf 50 MG/ML Auto-Injector [Idacio]) } Pack [Idacio Pen 40 MG/0.8 ML Starter Package for Crohn's Disease or Ulcerative Colitis] | BPCK | 7 | These highlights do not include all the information needed to use IDACIO safely and effectively. See full prescribing information for IDACIO. IDACIO® (adalimumab-aacf) injection, for subcutaneous use Initial U.S. Approval: 2022 IDACIO® (adalimumab-aacf) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between | 20260130 |
| 43de75ac-1a37-4609-9edd-68bda2448a47 | Idacio Pen 40 MG/0.8 ML - Starter Package for Crohn's Disease or Ulcerative Colitis (6 count) | PSN | 7 | These highlights do not include all the information needed to use IDACIO safely and effectively. See full prescribing information for IDACIO. IDACIO® (adalimumab-aacf) injection, for subcutaneous use Initial U.S. Approval: 2022 IDACIO® (adalimumab-aacf) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between | 20260130 |